Advertisement
Screener

TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVJF) Excess Tax Benefit from Share-based Compensation, Financing Activities

2.8 / 5 stars · 68/120 Roast Me

TEVA PHARMACEUTICAL INDUSTRIES LIMITED Excess Tax Benefit from Share-based Compensation, Financing Activities

TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVJF) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $14.00 million for the 12-month period ending 2010-12-31, per its 20-F filed 2011-02-15.

Discontinued › Notes › Compensation Related Costs

us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2011-02-15

  • TEVA PHARMACEUTICAL INDUSTRIES LIMITED excess tax benefit from share-based compensation, financing activities for the quarter ending 2010-12-31 was $3.00M, a 40.00% decline year-over-year.
  • TEVA PHARMACEUTICAL INDUSTRIES LIMITED excess tax benefit from share-based compensation, financing activities for the quarter ending 2010-09-30 was $1.00M, a 85.71% decline year-over-year.
  • TEVA PHARMACEUTICAL INDUSTRIES LIMITED excess tax benefit from share-based compensation, financing activities for the quarter ending 2010-06-30 was $3.00M.
  • TEVA PHARMACEUTICAL INDUSTRIES LIMITED excess tax benefit from share-based compensation, financing activities for the quarter ending 2010-03-31 was $7.00M, a 16.67% increase year-over-year.
Period endExcess Tax Benefit from Share-based Compensation, Financing Activities 3 monthExcess Tax Benefit from Share-based Compensation, Financing Activities 6 monthExcess Tax Benefit from Share-based Compensation, Financing Activities 9 monthExcess Tax Benefit from Share-based Compensation, Financing Activities 12 month
2010-12-31$3.00M
derived: 20-F 12 month − 6-K 9 month · filed 2011-02-15
$4.00M
derived: sum of 2 quarters · filed 2011-02-15
$7.00M
derived: sum of 3 quarters · filed 2011-02-15
$14.00M
20-F · filed 2011-02-15
2010-09-30$1.00M
derived: 6-K 9 month − 6-K 6 month · filed 2010-11-02
$4.00M
derived: sum of 2 quarters · filed 2010-11-02
$11.00M
6-K · filed 2010-11-02
$16.00M
derived: sum of 4 quarters · filed 2011-02-15
2010-06-30$3.00M
derived: 6-K 6 month − 6-K 3 month · filed 2010-07-27
$10.00M
6-K · filed 2010-07-27
$15.00M
derived: sum of 3 quarters · filed 2011-02-15
$22.00M
derived: sum of 4 quarters · filed 2011-02-15
2010-03-31$7.00M
6-K · filed 2010-05-04
$12.00M
derived: sum of 2 quarters · filed 2011-02-15
$19.00M
derived: sum of 3 quarters · filed 2011-02-15
$19.00M
derived: sum of 4 quarters · filed 2011-02-15
2009-12-31$5.00M
derived: 20-F 12 month − 6-K 9 month · filed 2011-02-15
$12.00M
derived: sum of 2 quarters · filed 2011-02-15
$12.00M
derived: sum of 3 quarters · filed 2011-02-15
$18.00M
20-F · filed 2011-02-15
2009-09-30$7.00M
derived: 6-K 9 month − 6-K 6 month · filed 2010-11-02
$7.00M
derived: sum of 2 quarters · filed 2010-11-02
$13.00M
6-K · filed 2010-11-02
$23.00M
derived: sum of 4 quarters · filed 2011-02-15
2009-06-30$0.00
derived: 6-K 6 month − 6-K 3 month · filed 2010-07-27
$6.00M
6-K · filed 2010-07-27
$16.00M
derived: sum of 3 quarters · filed 2011-02-15
$27.00M
derived: sum of 4 quarters · filed 2011-02-15
2009-03-31$6.00M
6-K · filed 2010-05-04
$16.00M
derived: sum of 2 quarters · filed 2011-02-15
$27.00M
derived: sum of 3 quarters · filed 2011-02-15
$30.00M
derived: sum of 4 quarters · filed 2011-02-15
2008-12-31$10.00M
derived: 20-F 12 month − 6-K 9 month · filed 2011-02-15
$21.00M
derived: sum of 2 quarters · filed 2011-02-15
$24.00M
derived: sum of 3 quarters · filed 2011-02-15
$33.00M
20-F · filed 2011-02-15
2008-09-30$11.00M
derived: 6-K 9 month − 6-K 6 month · filed 2009-11-03
$14.00M
derived: sum of 2 quarters · filed 2009-11-03
$23.00M
6-K · filed 2009-11-03
2008-06-30$3.00M
derived: 6-K 6 month − 6-K 3 month · filed 2009-07-29
$12.00M
6-K · filed 2009-07-29
2008-03-31$9.00M
6-K · filed 2009-05-07
2007-12-31$36.00M
20-F · filed 2010-02-22